Journal
PHARMACOGNOSY MAGAZINE
Volume 18, Issue 78, Pages 304-313Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/pm.pm_450_21
Keywords
Bisacurone; interleukin-6; OPG; osteoporosis; ovariectomy; RANKL; Runx2; tumor necrosis factor-alpha
Categories
Ask authors/readers for more resources
Bisacurone therapy significantly increased calcium content, reduced inflammatory cytokine levels, effectively promoted fracture healing, and improved bone quality in OVX-induced osteoporosis rats.
Background: Osteoporosis (OP) is a common disorder resulting in bone fragility and fracture. Due to OP, bone mass and microarchitectural bone tissues are damaged, increasing the risk of fracture. Objectives: To determine the efficacy of bisacurone in healing fractured bones and its inflammatory response in ovariectomy (OVX)-induced OP in female rats. Materials and Methods: After inducing fracture in femur bone, bisacurone (25, 50, and 100 mu g/kg) and alendronate (20 mg/kg) were orally administered to rats for 8 weeks. Subsequently, its fracture healing and anti-inflammatory potential were evaluated via assessment of various biochemical and molecular parameters. Results: Bisacurone therapy significantly (P < 0.05) increased the calcium content, serum calcium, and phosphorus in OVX-induced OP rats. It significantly (P < 0.05) reduced the serum alkaline phosphate (ALP); urine biochemical parameters such as urinary calcium, phosphorus, and creatinine; and inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). Moreover, bisacurone was found to be significantly (P < 0.05) effective in downregulating the bone turnover markers such as osteocalcin, receptor activator of nuclear factor-kappa-beta ligand (RANKL), peroxisome proliferator-activated receptor gamma (PPAR-gamma), and upregulating osteoprotegerin (OPG), runt-related transcription factor 2 (Runx2), and AMP-activated protein kinase (AMPK) in OVX-induced OP rats. Conclusion: Bisacurone effectively healed the fracture and improved the bone quality in arthritic conditions by reducing inflammatory cytokines and altering the level of bone turnover markers. Therefore, bisacurone therapy should be considered for the management of fracture healing process in the arthritic conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available